Filing Flows › Industries › Health Care › Services-Medical Laboratories
Services-Medical Laboratories SIC 8071
22 companies filing with the SEC under SIC 8071. Median revenue growth +25% year on year in Q3 2026 (middle half +9% to +41%, 16 companies). The growth model expects the industry's combined revenue to grow +12% in Q3 2026. 17 customer or supplier links named in annual reports.
Money flow: where the industry's revenue goes
Drawn in the browser: an estimate of where the industry's revenue goes — what it buys from other industries, the pay that reaches households, taxes and profit — beside its filed cash flow, two tiers of suppliers and its capital spending by kind of asset.
Open the industry: growth distribution, money flow, network →
Who sells to whom
Customers and suppliers named in the companies' annual reports; the share is of the supplier's revenue.
- DGX → Medicare & Medicaid 8% of the supplier's revenue, $883M
- CAI → Medicare & Medicaid 39% of the supplier's revenue, $317M
- NTRA → Medicare & Medicaid 13% of the supplier's revenue, $295M
- VCYT → Medicare & Medicaid 34% of the supplier's revenue, $176M
- CDNA → Medicare & Medicaid 46% of the supplier's revenue, $175M
- BDSX → Medicare & Medicaid 32% of the supplier's revenue, $28.3M
- XGN → Medicare & Medicaid 24% of the supplier's revenue, $16.0M
- PSNL → MRNA 22% of the supplier's revenue, $15.3M
- RDNT → U.S. government
- RDNT → Medicare & Medicaid
- TMO → CDNA
- ILMN → NTRA
- ILMN → GH
- ILMN → FLGT
- ILMN → GRAL
- ILMN → CAI
- TWST → GRAL
Growth model
Industry revenue, the same companies year on year; 80% ranges. Fitted on SEC filings and tested out of sample (how).
| Quarter | Growth Y/Y | Revenue | 80% range |
|---|---|---|---|
| Q3 2026 | +12.2% | $10.4B | $9.1B – $11.7B |
| Q4 2026 | +12.0% | $10.6B | $9.0B – $12.1B |
| Q1 2027 | +11.6% | $10.6B | $8.9B – $12.3B |
| Q2 2027 | +11.1% | $11.3B | $9.5B – $13.2B |
Capital spending and supply chain →
Companies
| Company | Quarterly revenue | Y/Y | Stage |
|---|---|---|---|
| LH Labcorp Holdings | $3.8B | +7% | mature |
| DGX Quest Diagnostics | $3.1B | +10% | mature |
| NTRA Natera | $794M | +34% | transition |
| FTRE Fortrea Holdings | $692M | -1% | mature |
| RDNT RadNet | $623M | — | transition |
| GH Guardant Health | $361M | +36% | deceleration |
| CAI Caris Life Sciences | $275M | +27% | deceleration |
| LMRI Lumexa Imaging Holdings | $264M | — | mature |
| VCYT Veracyte | $152M | +15% | transition |
| CDNA CareDx | $139M | +39% | deceleration |
| BLLN BillionToOne | $123M | +47% | deceleration |
| CSTL Castle Biosciences | $103M | +24% | transition |
| FLGT Fulgent Genetics | $90.4M | +8% | mature |
| CFOR CapForce | $50.0M | — | expansion |
| GRAL Grail | $37.5M | +4% | deceleration |
| PSNL Personalis | $25.6M | +77% | expansion |
| BDSX Biodesix | $24.0M | +10% | deceleration |
| XGN Exagen | $19.9M | — | transition |
| AMS American Shared Hospital Services | $8.4M | — | transition |
| BGLC BioNexus Gene Lab | $76K | — | transition |
| SERA Sera Prognostics | $42K | +162% | expansion |
| ACON Aclarion | $34K | +78% | expansion |
Growth from positive, comparable quarterly revenue as filed; industries are SEC Standard Industrial Classification codes. Data Nov 8, 2026.